These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35472771)

  • 1. Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus.
    Gru AA; Lim MS; Dogan A; Horwitz SM; Delabie J; Fu K; Peker D; Reddy VVB; Xu ML; Vij K; Slack GW; Miranda RN; Jagadeesh D; Lisano JM; Hsi ED; Torlakovic E
    Arch Pathol Lab Med; 2023 Jan; 147(1):79-86. PubMed ID: 35472771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemistry of Hodgkin and non-Hodgkin lymphomas with emphasis on the diagnostic significance of the BNH9 antibody reactivity with anaplastic large cell (CD30 positive) lymphomas.
    Carbone A; Gloghini A; Volpe R
    Cancer; 1992 Dec; 70(11):2691-8. PubMed ID: 1330287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.
    Bossard C; Dobay MP; Parrens M; Lamant L; Missiaglia E; Haioun C; Martin A; Fabiani B; Delarue R; Tournilhac O; Delorenzi M; Gaulard P; de Leval L
    Blood; 2014 Nov; 124(19):2983-6. PubMed ID: 25224410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas.
    Karube K; Kakimoto Y; Tonozuka Y; Ohshima K
    Expert Rev Hematol; 2021 Aug; 14(8):777-787. PubMed ID: 34263699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
    Jagadeesh D; Horwitz S; Bartlett NL; Kim Y; Jacobsen E; Duvic M; Little M; Trepicchio W; Fenton K; Onsum M; Lisano J; Advani R
    Oncologist; 2022 Oct; 27(10):864-873. PubMed ID: 35948003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis.
    Xu ML; Gabali A; Hsi ED; Fedoriw Y; Vij K; Salama ME; Ramchandren R; O'Malley D; Wick MR; Battistella M; Gru AA
    Am J Surg Pathol; 2020 Feb; 44(2):e1-e14. PubMed ID: 31567279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.
    Takahashi E; Tsuchida T; Baba S; Tsuzuki T; Shimauchi T; Tokura Y; Tamada Y; Nakamura S
    Pathol Int; 2020 Oct; 70(10):804-811. PubMed ID: 32783303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nodal Involvement by CD30
    Lezama LS; Gratzinger D
    Arch Pathol Lab Med; 2018 Jan; 142(1):139-142. PubMed ID: 29257929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy.
    Kawamoto K; Miyoshi H; Suzuki T; Sasaki Y; Yamada K; Yanagida E; Muto R; Kiryu M; Sone H; Seto M; Ohshima K; Takizawa J
    Hematol Oncol; 2018 Feb; 36(1):166-173. PubMed ID: 29052238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL).
    Ranuhardy D; Suzanna E; Sari RM; Hadisantoso DW; Andalucia R; Abdillah A
    Acta Med Indones; 2018 Apr; 50(2):104-109. PubMed ID: 29950528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of a new notation to visualize flow cytometry analysis results: first preliminary comparison with immunohistochemistry to detect CD30 expression on T-cell lymphoma cells.
    Fujishima F; Fukuhara N; Katsushima H; Nakamura Y; Harigae H; Sasano H; Ichinohasama R
    BMC Cancer; 2021 Dec; 21(1):1352. PubMed ID: 34930176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD30 Cross-Reactivity and Expression in Feline Normal Tissues and Lymphomas.
    Carminato A; Tecilla M; Roccabianca P; Zanardello C; Melchiotti E; Capello K; Vascellari M
    Vet Pathol; 2020 Jan; 57(1):49-55. PubMed ID: 31640480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma.
    O'Malley DP; Dogan A; Fedoriw Y; Medeiros LJ; Ok CY; Salama ME
    Ann Diagn Pathol; 2019 Apr; 39():105-110. PubMed ID: 30802809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas.
    Miettinen M
    Arch Pathol Lab Med; 1992 Nov; 116(11):1197-201. PubMed ID: 1332642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standardization of CD30 immunohistochemistry staining among three automated immunostaining platforms.
    Seki M; Satou A; Funato R; Tamaki T; Wada N; Nakada N; Matsumoto H; Nakazato I; Wada E; Sakurai K; Tsuzuki T; Karube K
    Pathol Int; 2024 Sep; 74(9):530-537. PubMed ID: 39171823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D connectomes of reactive and neoplastic CD30 positive lymphoid cells and surrounding cell types.
    Lumer L; Wurzel P; Scharf S; Schäfer H; Ackermann J; Koch I; Hansmann ML
    Acta Histochem; 2021 Jul; 123(5):151750. PubMed ID: 34233254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
    Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
    Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.
    Bisig B; de Reyniès A; Bonnet C; Sujobert P; Rickman DS; Marafioti T; Delsol G; Lamant L; Gaulard P; de Leval L
    Haematologica; 2013 Aug; 98(8):1250-8. PubMed ID: 23716562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD30 expression in follicular lymphoma.
    Piris M; Gatter KC; Mason DY
    Histopathology; 1991 Jan; 18(1):25-9. PubMed ID: 1849500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment.
    Koens L; van de Ven PM; Hijmering NJ; Kersten MJ; Diepstra A; Chamuleau M; de Jong D
    Histopathology; 2018 Sep; 73(3):473-482. PubMed ID: 29758590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.